Q3504
Quazinone
powder
别名:
Ro 13-6438
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式（希尔记法）:
C11H10ClN3O
化学文摘社编号:
分子量:
235.67
UNSPSC Code:
41106305
PubChem Substance ID:
MDL number:
assay
≥98% (TLC)
form
powder
color
white
solubility
ethanol: 1 mg/mL
SMILES string
C[C@H]1N2Cc3c(Cl)cccc3N=C2NC1=O
InChI
1S/C11H10ClN3O/c1-6-10(16)14-11-13-9-4-2-3-8(12)7(9)5-15(6)11/h2-4,6H,5H2,1H3,(H,13,14,16)/t6-/m1/s1
InChI key
BHZFZYLBVSWUMT-ZCFIWIBFSA-N
Gene Information
human ... PDE3A(5139), PDE3B(5140)
Biochem/physiol Actions
Phosphodiesterase III (PDE3) inhibitor.
Features and Benefits
This compound was developed by Roche. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
存储类别
13 - Non Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
法规信息
新产品
此项目有
[Positive inotropic therapy of cardiac failure: old and new drugs, controversies and tests].
C Sfrisi et al.
La Clinica terapeutica, 111(2), 159-167 (1984-10-31)
S Braun et al.
Drugs under experimental and clinical research, 12(5), 381-384 (1986-01-01)
The chemical class 1,5 dihydroimidazo (2,1-6) guinazolin-2(3H)ones has been shown to have positive inotropic activity, some of its members displaying a favourable ratio between positive inotropic and chronotropic activity. This study was designed to determine the cardiovascular properties of Ro
M Komajda et al.
Fundamental & clinical pharmacology, 1(6), 459-470 (1987-01-01)
The dose-response for the new cardiotonic agent RO13-6438 was studied in 6 patients with grade III or IV congestive heart failure. Oral doses of 10, 20, or 30 mg of RO 13-6438 were administered on 3 consecutive days in accordance